Pretreatment serum FGF-23 levels predict the efficacy of calcitriol therapy in dialysis patients
- 1 March 2005
- journal article
- Published by Elsevier in Kidney International
- Vol. 67 (3) , 1120-1125
- https://doi.org/10.1111/j.1523-1755.2005.00178.x
Abstract
No abstract availableKeywords
This publication has 36 references indexed in Scilit:
- Differential regulation of PHEX expression in bone and parathyroid gland by chronic renal insufficiency and 1,25-dihydroxyvitamin D3American Journal of Physiology-Renal Physiology, 2004
- Intact PTH assay overestimates true 1-84 PTH levels after maxacalcitol therapy in dialysis patients with secondary hyperparathyroidismNephrology Dialysis Transplantation, 2004
- FGF-23 Is a Potent Regulator of Vitamin D Metabolism and Phosphate HomeostasisJournal of Bone and Mineral Research, 2004
- Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteersKidney International, 2003
- Regulation of Fibroblastic Growth Factor 23 Expression but Not Degradation by PHEXJournal of Biological Chemistry, 2003
- Fibroblast Growth Factor 23 in Oncogenic Osteomalacia and X-Linked HypophosphatemiaNew England Journal of Medicine, 2003
- Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidismKidney International, 2003
- Reduced p21, p27 and vitamin D receptor in the nodular hyperplasia in patients with advanced secondary hyperparathyroidism1Kidney International, 2002
- Pathogenesis of refractory secondary hyperparathyroidismKidney International, 2002
- Identification of a Novel Fibroblast Growth Factor, FGF-23, Preferentially Expressed in the Ventrolateral Thalamic Nucleus of the BrainBiochemical and Biophysical Research Communications, 2000